Article

Rayner's Recently Acquired Ophteis OVD Range and What This Means for Cataract Surgery

Professor Steve Arshinoff and Rayner CEO Tim Clover announce Rayner's recent acquisition of the Ophteis OVD range at the Company's celebratory event, held at the 2015 ESCRS in Barcelona.

Professor Steve Arshinoff and Rayner CEO Tim Clover announce Rayner's recent acquisition of the Ophteis OVD range at the Company's celebratory event, held at the 2015 ESCRS in Barcelona. Professor Arshinoff goes on to talk about the importance of OVDs in cataract surgery and how there is a gap in the market when it comes to innovation in this area. For more information please watch our video.

For further information on the Ophteis OVD range, please visit www.rayner.com/en/ovd 

Back to the Eye-to-Eye Innovation Series

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
© 2025 MJH Life Sciences

All rights reserved.